H
Hugo M. Horlings
Researcher at Netherlands Cancer Institute
Publications - 129
Citations - 18740
Hugo M. Horlings is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 46, co-authored 106 publications receiving 15805 citations. Previous affiliations of Hugo M. Horlings include BC Cancer Agency & University of Amsterdam.
Papers
More filters
Journal ArticleDOI
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis
Liesbeth C.W. Vredeveld,Patricia A. Possik,Marjon A. Smit,Katrin Meissl,Chrysiis Michaloglou,Hugo M. Horlings,Abderrahim Ajouaou,Pim C. Kortman,David Dankort,Martin McMahon,Wolter J. Mooi,Daniel S. Peeper +11 more
TL;DR: It is shown here that PTEN depletion abrogates BRAF(V600E)-induced senescence in human fibroblasts and melanocytes, and demonstrated that PI3K pathway activation serves as a rate-limiting event in this setting, acting at least in part by abrogating OIS.
Journal ArticleDOI
Genetic regulators of large-scale transcriptional signatures in cancer
Adam S. Adler,Meihong Lin,Hugo M. Horlings,Dimitry S.A. Nuyten,Marc J. van de Vijver,Howard Y. Chang +5 more
TL;DR: This method shows that the wound response signature, a poor-prognosis expression pattern of 512 genes in breast cancer, is induced by coordinate amplifications of MYC and CSN5 (also known as JAB1 or COPS5).
Journal ArticleDOI
A case of meningoencephalitis by the relapsing fever spirochaete Borrelia miyamotoi in Europe
Joppe W. Hovius,Bob de Wever,Maaike Sohne,Matthijs C. Brouwer,Jeroen Coumou,Alex Wagemakers,Anneke Oei,Henrike Knol,Sukanya Narasimhan,Caspar J. Hodiamont,Setareh Jahfari,Steven T. Pals,Hugo M. Horlings,Erol Fikrig,Hein Sprong,Marinus H. J. van Oers +15 more
TL;DR: Supported by the recent evidence of the presence of B miyamotoi in Ixodes ricinus ticks across Europe, the relation in time of the patient’s symptoms with the tick bites, and his immunocompromised status, the patient was treated for a possible Lyme neuroborreliosis with once daily 2000 mg ceftriaxone intravenously for 2 weeks and fully recovered.
Journal ArticleDOI
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
Liqin Wang,Rodrigo Leite de Oliveira,Sanne Huijberts,Evert Bosdriesz,Nora Pencheva,Diede Brunen,Astrid Bosma,Ji-Ying Song,John Zevenhoven,G Tjitske Los-de Vries,Hugo M. Horlings,Bastiaan Nuijen,Jos H. Beijnen,Jan H.M. Schellens,René Bernards +14 more
TL;DR: In a study in patients with advanced BRAF+MEK inhibitor-resistant melanoma, vorinostat can selectively ablate drug-resistant tumor cells, providing clinical proof of concept for the novel therapy identified here.
Journal ArticleDOI
Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes
Yi Kan Wang,Ali Bashashati,Michael S. Anglesio,Dawn R. Cochrane,Diljot Grewal,Diljot Grewal,Gavin Ha,Andrew McPherson,Andrew McPherson,Hugo M. Horlings,Janine Senz,Leah M Prentice,Anthony N. Karnezis,Daniel Lai,Mohamed R Aniba,Allen W. Zhang,Allen W. Zhang,Allen W. Zhang,Karey Shumansky,Celia Siu,Adrian Wan,Melissa K. McConechy,Hector Li-Chang,Alicia A. Tone,Diane Provencher,Manon de Ladurantaye,Hubert Fleury,Aikou Okamoto,Satoshi Yanagida,Nozomu Yanaihara,Misato Saito,Andrew J. Mungall,Richard A. Moore,Marco A. Marra,Marco A. Marra,C. Blake Gilks,C. Blake Gilks,Anne-Marie Mes-Masson,Jessica N. McAlpine,Samuel Aparicio,Samuel Aparicio,David G. Huntsman,David G. Huntsman,Sohrab P. Shah,Sohrab P. Shah +44 more
TL;DR: This work establishes the potency of the somatic genome, reflective of diverse DNA repair deficiencies, to stratify ovarian cancers into distinct biological strata within the major histotypes.